Vasculopathy, Inflammation and Systemic Sclerosis
VISS
1 other identifier
interventional
350
1 country
1
Brief Summary
It is a study of basic research with mechanistically objectives and including clinical biological samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2012
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2012
CompletedFirst Submitted
Initial submission to the registry
December 29, 2014
CompletedFirst Posted
Study publicly available on registry
September 29, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedApril 7, 2017
April 1, 2017
4.8 years
December 29, 2014
April 5, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of OX40L expression in endothelial cells and skin biopsies.
Day 1
Study Arms (3)
subjects SSc diagnosed
EXPERIMENTALsubjects Localised sclerosis diagnosed
EXPERIMENTALsubjects Sc
EXPERIMENTALInterventions
* biological features of the standard follow-up * 2 more blood tube for the biological collection (serum and PBMC)
Eligibility Criteria
You may qualify if:
- Age from 18 to 75.
- SSc diagnosed according to the American College of Rheumatology (ACR) criteria.
- With skin manifestations since less than 10 years.
- Localised sclerosis (LSc) diagnosed, morphea type.
You may not qualify if:
- Age inferior to 18 or upper than 75.
- Skin manifestations since more than 10 years.
- Haemostasis diseases (independent from treatments).
- Stem cell transplant.
- Immunosuppressive treatments in the last 6 months.
- Associate autoimmune disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Bordeauxlead
- Societe Francaise de Rhumatologiecollaborator
Study Sites (1)
Service de Rhumatologie - Tripode - Hôpital Pellegrin
Bordeaux, Bordeaux, 33076, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marie-Elise TRUCHETET, MD
University Hospital Bordeaux, France
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2014
First Posted
September 29, 2015
Study Start
March 1, 2012
Primary Completion
December 1, 2016
Study Completion
December 1, 2016
Last Updated
April 7, 2017
Record last verified: 2017-04